Sharekhan's research report on Ipca Laboratories
Strong growth outlook across both the API and formulations space would be the key growth driver. Resolution of the USFDA hurdles would be a positive and will lead to earnings upgrades. We expect the company to report a Sales and PAT CAGR of 16% and 20% respectively between FY2020 to FY2022.
Outlook
We maintain Buy recommendation on IPCA Labs with a revised PT of Rs 1590. Ipca reported impressive performance for Q3FY2020 with the results ahead of estimates.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
Read More
